Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion

Merck NYSE:MRK said on Monday it would pay up to $2.13 billion under a global licensing deal with China's SciBrunch Therapeutics for rights to develop, manufacture and sell an experimental cancer treatment.The deal underscores Merck's efforts to broaden its cancer drug pipeline as it prepares for p…